Key result
Therapeutic paroxetine lacks significant hemodynamic or electrophysiological effects in depressed patients and healthy men.
Why the study?
Does paroxetine have lower cardiovascular toxicity compared to tricyclic antidepressants in depressive patients and healthy men?
Does paroxetine have lower cardiovascular toxicity compared to tricyclic antidepressants in depressive patients and healthy men?
Paroxetine appears to have a safer cardiovascular profile compared to classical tricyclic antidepressants, lacking significant haemodynamic or electrophysiological effects.
Answers are grounded in this paper and cite their sources.
Supports paroxetine's cardiovascular safety versus tricyclics in reviewed data; leaves open randomized confirmation before practice change.
The classical tricyclic antidepressant drugs effectively relieve the symptoms of depression, but they have the potential to be severely toxic to the cardiovascular system--including postural hypotension after therapeutic doses and lethal arrhythmias after overdosage. Paroxetine has been shown to be of similar efficacy to the tricyclic antidepressants but has lower cardiovascular toxicity in animal models and has no effects on heart rate, blood pressure or the electrocardiogram in healthy men receiving single 20-40 mg doses. The results of two contrasting studies in depressive patients and healthy men provide strong evidence that therapeutic doses of paroxetine lack any important haemodynamic or electrophysiological effects.
No takes yet. Share an insight, caveat, or question.
Warrington et al. (1992) conducted a review in Depression. Paroxetine vs. Tricyclic antidepressants was evaluated on Haemodynamic or electrophysiological effects. Therapeutic doses of paroxetine lack any important haemodynamic or electrophysiological effects in depressive patients and healthy men.
Synapse has enriched 10 related papers. Consider them for comparative context: